Medincell

Medincell, a pharmaceutical preparation manufacturing company based in France, reported its latest emissions data for 2025. The company's total emissions for that year were approximately 307.36 million kg CO2e. This figure includes Scope 1 emissions of approximately 184,000 kg CO2e, Scope 2 emissions (market-based) of about 738,000 kg CO2e, and substantial Scope 3 emissions totalling approximately 306.44 million kg CO2e. Key contributors to Scope 3 emissions included purchased goods and services (about 223.05 million kg CO2e), business travel (about 39.86 million kg CO2e), and capital goods (approximately 24.61 million kg CO2e).

In the preceding year, 2024, Medincell's total emissions were approximately 279.40 million kg CO2e. This comprised Scope 1 emissions of around 98,000 kg CO2e, Scope 2 emissions (market-based) of about 1.13 million kg CO2e, and Scope 3 emissions of approximately 278.17 million kg CO2e.

For 2023, the company reported Scope 2 market-based emissions of approximately 12,860 kg CO2e and significant Scope 3 emissions, including about 5.12 million kg CO2e from purchased goods and services, 482,000 kg CO2e from capital goods, and 248,000 kg CO2e from business travel. Medincell has also reported emissions for earlier years, including 2022, 2021, 2020, and 2019, showing a growing trend in reported emissions as their disclosure becomes more comprehensive, particularly concerning Scope 3.

Medincell has not publicly disclosed any specific reduction targets or commitments, such as Science-Based Targets (SBTi), nor has it joined initiatives like the Climate Pledge. All reported emissions data originates directly from Medincell S.A.